Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main page
Recent changes
Random page
Help about MediaWiki
Special pages
Surgopaedia
Search
Search
Appearance
Create account
Log in
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Editing
Hyperparathyroidism
(section)
Page
Discussion
English
Read
Edit
Edit source
View history
Tools
Tools
move to sidebar
hide
Actions
Read
Edit
Edit source
View history
General
What links here
Related changes
Page information
Appearance
move to sidebar
hide
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== '''Primary: autonomous overproduction by one or more abnormal parathyroid glands (most common type)''' == * Risk factors ** Female (4:1) ** Age 50-60 ** Exposure to external beam radiation in the cervical region, with a latency period of 15-40 years *** Exposure during nuclear accidents *** Exposure during external radiotherapy *** Exposure during RAI ** Lithium therapy *** Decreases the parathyroid cells' sensitivity to calcium by interfering with the CaSR *** Usually stopping lithium reverts the calcium to normal ** Thiazide diuretics *** If the calcium remains abnormal after stopping the drug, treat it as unrelated * Aetiology ** 80% of PHPT results from clonal expansion of Chief cells in a single gland (parathyroid adenoma) ** 15% from four-gland parathyroid hyperplasia *** ** 4% adenomatous expansion in two or three of the four glands ** 1% parathyroid carcinoma *** Very high blood calcium and PTH levels (>14mg/dL and >300pg/mL respectively) * Pathophysiology ** Increased serum calcium levels from PTH-mediated increases in bone resorption, renal calcium reabsorption, and indirectly from increased dietary absorption ** This should normally suppress PTH production, but parathyroid cells in parathyroid adenoma/carcinoma have a lower than normal sensitivity to the inhibitory action of calcium, so a higher than normal calcium level is maintained ** With parathyroid hyperplasia, the cells have the same sensitivity to calcium, but there are more of them, which is sufficient to cause hypercalcaemia ** Multi-gland disease (either four-gland hyperplasia or double adenoma) occurs in about 10-15% of all patients with PHPT * Genetic syndromes (3-5% of all patients with PHPT) ** MEN1: PHPT in 100% ** MEN 2a: PHPT in 20-30% ** Familial isolated HPT (FIHP) *** Autosomal dominant ** HPT-JT - primary HPT in 80%, ossifying fibromas of mandible and maxilla, renal cysts, hamartomas, Wilms tumours, uterine tumours. Mutation in CDC73 leading to a defect in parafibromin. * Presentation ** 80% diagnosed from incidental hypercalcaemia ** 35% of patients have objective end-organ effects at time of diagnosis; 62% develop end-organ effects within 5 years of diagnosis * * Diagnosis ** Defined by hypercalcaemia associated with an elevated intact PTH level or inappropriately normal intact PTH level *** Differentials for high calcium and PTH: **** '''Primary vitamin D deficiency''' - if vitamin D is low, this should be fixed with supplementation for six months before retesting for PHPT **** '''Familial Hypocalciuric Hypercalcaemia''' - need to exclude with 24 hour urine calcium levels (<100mg in 24 hours is diagnostic. Most PHPT patients will have high urine calcium, by contrast) ***** Rare autosomal dominant disorder affecting renal CaSR that results in a higher set point for renal calcium excretion, hypocalciuria, asymptomatic hypercalcaemia, and normal or mildly elevated PTH levels. ***** Won't have the clinical manifestations of primary HPT ***** High penetrance - if they have it, they will normally develop high calcium by the age of 30, so it is uncommon to be the reason a post-menopausal woman is getting symptomatic hypercalcaemia ***** No treatment is required **** '''Prolonged lithium or thiazide therapy - see above''' **** '''Tertiary hyperparathyroidism''' ** Normal calcium and high PTH is a recognised variant - generally found during workup for kidney stones. Up to 16% of those patients will progress to standard PHPT *** Consider other causes of elevated PTH - vitamin D deficiency, renal insufficiency, primary hypercalciuria, malabsorption syndromes, bisphosphonates, denosumab ** High calcium and normal PTH is another variant - normohormonal HPT. This is very uncommon and something of a diagnosis of exclusion. Rule out other causes of hypercalcaemia and obtain biochemical measurements at multiple time points. Hard to know who to operate on, but consider operating on those with positive localising studies. Same signs and symptoms, with similar cure rates after surgery, are reported. * Workup ** If PHPT is suspected, consider parathyroid adenoma, parathyroid hyperplasia, and parathyroid carcinoma *** Serum total calcium (classically on three separate occasions) *** Intact PTH *** Creatinine *** 25(OH)D levels *** LFTs for albumin and ALP (marker of bone turnover) *** Serum phosphate (low in 50% of patients with primary HPT) *** Parathyroid imaging has no role in confirming or excluding the diagnosis of HPT ** After diagnosis of PHPT is confirmed: *** All patients should be screened for osteoporosis/osteopaenia with DXA bone mineral density scan *** 24-hour urine calcium and creatinine (exclude FHH, and check indication for surgery) - done for every patient at Alfred *** Abdominal imaging to look for kidney stones *** Vertebral spine assessment (can be seen on DXA) *** Genetic testing (MEN1) - patients with PHPT <40yo with multi-gland disease, and patients with either a family history PHPT or syndromes associated with it *** Parathyroid imaging - helps focus the exploration and to identify ectopic parathyroid glands, but does not alter the recommendation for exploration **** Start off with USS and Sestamibi-SPECT **** See 'thyroid imaging' section for further * Treatment ** Approach *** If meet an indication for surgery - surgery *** If not - surveillance with six-monthly bloods and USS *** If meet an indication for surgery but can't or won't have surgery - medical treatment ** Indications for surgery: *** Symptomatic/complicated hypercalcaemia 'stones, bones, abdominal groans, psychiatric overtones' **** Nephrolithiasis **** Fractures, osteoporosis/osteopaenia **** Depression/other neurologic symptoms including trouble concentrating **** Abdominal pain - PUD, pancreatitis *** Asymptomatic PHPT **** Age <50 (more cost-effective to operate than surveil) **** Serum calcium >0.25mmol/L above ULN **** 24 hour urine calcium >400mg (10mmol) **** eGFR < 60 or nephrolithiasis/nephrocalcinosis **** BMD with T-score <-2.5 or significant reduction or documented vertebral fracture **** When active surveillance and routine long-term follow-up is not a good option ** Medical treatment *** For patients who meet surgical criteria but aren't candidates *** Indication: symptomatic/severe hypercalcaemia: cinacalcet (expensive, non-durable) **** Binds to the calcium-sensing receptor on parathyroid cells to increase its sensitivity for the high serum calcium, and thus reduce serum PTH *** Indication: osteoporosis: bisphosphonates (alendronate) *** If neither of the above, then use neither ** Non-op management for those asymptomatic patients not having surgery *** Annual serum calcium and creatinine *** Bone density every one to two years *** Investigate symptoms that may suggest develop of an indication for surgery *** If progression, surgery *** Preventative measures **** Avoid thiazide diuretics + lithium **** Encourage physical activity to minimise bone resorption **** Encourage adequate hydration to prevent nephrolithiasis **** Maintain moderate calcium and vitamin d intake * Localisation ** Concordant USS Technitium-99m sestamibi scan +/- SPECT has a sensitivity 94-99% for finding a single adenoma ** Sestamibi can also locate ectopic disease, including abnormal inferior parathyroid glands descending into mediastinum ** Other modalities *** 4D CT (use if USS and sestamibi fail) *** MRI *** Venography with venous sampling ** If unable to localise with imaging: often have multi-gland disease, and should undergo bilateral neck/four gland exploration ** Intra-operative adjuncts *** Blood PTH testing - half life is 2-4 minutes, so levels should drop rapidly after successful excision. Failure to drop should prompt further exploration. Successful drop should conclude operation and remove need for further exploration. *** Gamma probe parathyroid adenoma localisation - sestamibi is preferentially retained by parathyroid glands compared to thyroid tissue. However this is apparently not that useful in practice. ** * Prognosis/outcomes ** Cure rates (defined as normal calcium at 6 months) 95-99% ** Surgical cure is followed by increased BMD by 2-4% in the first year ** Decreases hip and wrist fracture by 50-64% at 10 years ** Decreased rate of recurrent kidney stones ** Further decline in eGFR will be prevented ** Neurocognitive symptoms attributed to HPT show variable improvement
Summary:
Please note that all contributions to Surgopaedia may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Surgopaedia:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Search
Search
Editing
Hyperparathyroidism
(section)
Add topic